

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
**RESPONSE UNDER RULE 116**  
**EXPEDITED HANDLING PROCEDURES**

AF/1647


In re Patent Application of

ELMORE

Serial No. 08/981,087

Filed: May 27, 1998

Title: TYPE F BOTULINUM TOXIN AND USE THEREOF



Corres. and Mail  
**BOX AF**

Atty Dkt# 1498-133

C#/M#

Group Art Unit: 1647

Examiner: Turner, S.

Date: September 5, 2001

**RECEIVED**

SEP 10 2001

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number  
Previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number  
Previously paid for 3 (at least 3) = 0 x \$ 80.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$270.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this  
Paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$710.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

**SUBTOTAL \$ 0.00**

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

**TOTAL FEE ENCLOSED \$ 0.00**

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor  
Arlington, Virginia 22201-4714

NIXON & VANDERHYE P.C.

By Atty.: B. J. Sadoff, Reg. No. 36,663

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

FC: 703 \$110.00 CR

BJS:ea

Signature:

RECEIVED

SEP 10 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

ELMORE

Serial No. 08/981,087

Filed: May 27, 1998

For: TYPE F BOTULINUM TOXIN AND USE THEREOF



Atty. Ref.: 1498-133

Group: 1647

Examiner: Turner, S.

\* \* \* \* \*

September 5, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**AMENDMENT UNDER RULE 116**

Responsive to the Official Action dated June 5, 2001, entry and consideration of the following amendments and remarks are requested.

**IN THE CLAIMS**

Amend the claims as follows.

Cancel claims 3, 4, 20, 22, 23, 24 and 27 without prejudice.

Amend the claims as follows:

5. (Four Times Amended) An isolated polypeptide comprising a sequence of amino acids selected from the group consisting of:

- (a) amino acids 848-1278 of a type F botulinum toxin (SEQ ID NO: 1)
- (b) amino acids 848-991 of a type F botulinum toxin (SEQ ID NO: 2)
- (c) amino acids 992-1135 of a type F botulinum toxin (SEQ ID NO: 3), and;

21/3  
A.G.  
9/11/01  
(NE)

Please  
do not enter  
10-107